The effect of 6-mercaptopurine on natural killer-cell activities in Crohn's disease.
The effect of 6-mercaptopurine on natural killer-cell activities in Crohn's disease.
复制标题
6-巯基嘌呤对克罗恩病自然杀伤细胞活性的影响。
DOI：
10.1007/bf00915512
复制
发表时间：
1985
影响因子：
9.1
通讯作者：
Targan,S
中科院分区：
文献类型：
--
作者：
Brogan,M;Hiserodt,J;Oliver,M;Stevens,R;Korelitz,B;Targan,S
对长期接受6-巯基嘌呤治疗（超过4个月）的克罗恩病患者外周血自然杀伤细胞活性进行评估。研究了自然杀伤细胞对K-562肿瘤细胞靶点的细胞溶解活性，以及自然杀伤细胞对淋巴母细胞样b细胞抗体产生的抑制作用。此外，研究了这些患者在体内增强免疫后产生抗破伤风特异性IgG抗体的淋巴母细胞样B细胞的能力。与正常人、疾病对照组和未接受6-巯基嘌呤治疗的克罗恩病患者相比，接受6-巯基嘌呤治疗的克罗恩病患者外周血抗K-562靶标的自然杀伤细胞活性显著降低。与正常对照组相比，6-巯基嘌呤治疗的患者自然杀伤细胞对淋巴母细胞样b细胞抗体产生的抑制也同样降低。相比之下，接受6-巯基嘌呤治疗的克罗恩病患者体内产生的淋巴母细胞样b细胞抗体反应与正常人相比没有下降，而未接受6-巯基嘌呤治疗的克罗恩病患者体内产生的IgG抗破伤风抗体反应明显受损。这些发现表明，6-巯基嘌呤治疗克罗恩病影响到几个淋巴细胞亚群，导致自然杀伤细胞对K-562靶细胞的细胞毒活性下降，自然杀伤细胞抑制淋巴母细胞样b细胞抗体产生的能力下降，以及破伤风类毒素增强免疫后体液免疫反应的改善。
Crohn's disease patients on long-term 6-mercaptopurine therapy (more than 4 months) were evaluated for activity of peripheral blood natural killer cells. Natural killer-cell cytolytic activity against K-562 tumor-cell targets was examined, as was natural killer-cell suppression of lymphoblastoid B-cell antibody production. In addition, these patients were studied for their ability to generate antitetanus-specific IgG antibody-producing lymphoblastoid B cells followingin vivobooster immunization. Crohn's disease patients on 6-mercaptopurine therapy had significant reductions in peripheral blood natural killer-cell activity against K-562 targets compared to normals, disease controls, and Crohn's disease patients not on 6-mercaptopurine. Natural killer-cell suppression of lymphoblastoid B-cell antibody production was like-wise decreased in 6-mercaptopurine-treated patients compared to normal controls. In contrast, thein vivogenerated lymphoblastoid B-cell antibody responses of Crohn's disease patients on 6-mercaptopurine therapy were not decreased compared to normal, while Crohn's disease patients not on 6-mercaptopurine therapy had significantly impaired IgG antitetanus antibody responses. These findings suggest that 6-mercaptopurine therapy in Crohn's disease affects several lymphoid subpopulations, resulting in a decreased natural killer-cell cytotoxic activity against K-562 target cells and a decreased natural killer-cell ability to suppress lymphoblastoid B-cell antibody production, as well as an improved humoral immune response following tetanus toxoid booster immunization.